Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Share-based Compensation (2016 - 2025)

Integra Lifesciences Holdings' Share-based Compensation history spans 17 years, with the latest figure at $5.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 18.37% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $18.6 million, down 23.77%, while the annual FY2025 figure was $18.6 million, 23.77% down from the prior year.
  • Share-based Compensation for Q4 2025 was $5.8 million at Integra Lifesciences Holdings, up from $5.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $15.7 million in Q2 2021 and bottomed at $1.9 million in Q1 2025.
  • The 5-year median for Share-based Compensation is $5.8 million (2023), against an average of $6.4 million.
  • The largest annual shift saw Share-based Compensation surged 203.54% in 2021 before it tumbled 66.6% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.4 million in 2021, then decreased by 10.9% to $5.7 million in 2022, then rose by 1.08% to $5.8 million in 2023, then rose by 23.46% to $7.2 million in 2024, then decreased by 18.37% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Share-based Compensation are $5.8 million (Q4 2025), $5.6 million (Q3 2025), and $5.3 million (Q2 2025).